<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110789">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01692665</url>
  </required_header>
  <id_info>
    <org_study_id>1-2012-0031</org_study_id>
    <nct_id>NCT01692665</nct_id>
  </id_info>
  <brief_title>Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ocular aberration may play a role in determining optical quality. Recently performed study
      reported that ocular aberration of preocular tear film would be important factor in not only
      diagnosing the dry eye but also determining the efficacy of treatment. Therefore, in this
      study, the investigators will aim to prove the improvement of quality of vision via ocular
      aberration changes indirectly after the proper treatment for moderate and severe meibomian
      gland dysfunction. Also, the investigators will evaluate the changes of keratometric values
      after treatment for moderate and severe meibomian gland dysfunction, which could be
      demonstrated by autokeratometry, IOLMaster, Pentacam, and iTrace.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Changes of keratometric value and ocular aberration</measure>
    <time_frame>a minimum of four minutes, once or twice dailybefore treatment, after 1 month, and after 2 months of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)</condition>
  <arm_group>
    <arm_group_label>stage 3 or stage 4 meibomiang gland dysfunction patients</arm_group_label>
    <description>stage 3 or stage 4 meibomiang gland dysfunction patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        stage 3 or stage 4 meibomiang gland dysfunction patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1) stage 3 or 4 meibomian gland dysfunction

        Exclusion Criteria:

          1. history of previous ocular or intraocular surgery

          2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune
             disease,

          3. history of intolerance or hypersensitivity to any component of the study medications,

          4. wearing contact lenses during the study period, presence of current punctal
             occlusion,

          5. pregnancy, lactating women, and children.

          6. Additionally, patients were excluded if they were using any topical ocular or
             systemic medication that could be used for the treatment MGD or dry eye, including
             topical or oral antibiotics, topical cyclosporine A, topical or oral steroids,
             topical non-steroidal anti-inflammatory drugs, topical ocular allergy medications or
             artificial tears
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>September 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meibomian gland dysfunction</keyword>
  <keyword>keratometric value</keyword>
  <keyword>ocular aberration</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
